Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide cardiovascular outcomes study in type 2 diabetes
2014-001824-32Phase 4Completed
- Sponsor
- GSK
- Start
- Jan 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Albiglutide + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first occurrence of major adverse cardiovascular events. Started Jan 2015; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-001824-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001824-32.